Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Novo-Nordisk A/S (NYSE: NVO).

Full DD Report for NVO

You must become a subscriber to view this report.


Recent News from (NYSE: NVO)

Vanguard Health Care: A Good Place To Invest For The Future
Last week, the Centers for Disease Control reported that the average life expectancy in the United States has fallen for the third straight year. The primary reasons that the agency gave for this trend was an increase in deaths from suicide, the flu, diabetes, and drug abuse. In short, we ha...
Source: SeekingAlpha
Date: December, 04 2018 14:02
Performance Review: Stocks That Topped My Factor-Based Quality Ranking Model
Background Last December, I wrote this article describing how I pick stocks to invest for the long run using a quality-focused ranking approach. The ranking model contained a few quantifiable factors covering different dimensions of business fundamentals, some of which I would like to reit...
Source: SeekingAlpha
Date: December, 04 2018 09:05
Nicholas Ward's Dividend Growth Portfolio: October Update
Last month, I posted my quarterly results and said that I would try and do a better job of posting regular portfolio updates for those readers/followers who don’t track Seeking Alpha on a daily basis and miss my trade-related stock talks. Well, here we go. October was a crazy month fo...
Source: SeekingAlpha
Date: November, 05 2018 07:45
Novo Nordisk: Diabetes Care Driving Current And Forward Results
On Thursday, November 1, 2018, diabetes-focused pharmaceutical giant Novo Nordisk ( NVO ) announced its third quarter 2018 earnings results . The market appeared to like these results, driving the shares up 3% in the pre-market session following the announcement. Many in the financial media c...
Source: SeekingAlpha
Date: November, 04 2018 17:08
Xeris Pharmaceuticals Is An Attractive Buy Opportunity In 2018
Xeris Pharmaceuticals ( XERS ) is standing at a cusp of a transformation, from being a clinical-stage company to a commercial organization. And these times are always exciting for both biotech companies as well as investors, as they present a unique opportunity of significant upside potential ...
Source: SeekingAlpha
Date: November, 02 2018 16:31
Novo teams up with Embark in obesity; shares up 1% premarket
Novo Nordisk (NYSE: NVO ) inks a research collaboration with Copenhagen-based Embark Biotech ApS aimed at discovering new treatments for obesity and its related pathologies via mechanisms that increase energy expenditure. More news on: Novo Nordisk A/S, Healthcare stocks news, Stocks on ...
Source: SeekingAlpha
Date: November, 02 2018 07:04
Novo Nordisk A/S (NVO) CEO Lars Fruergaard Jørgensen on Q3 2018 Results - Earnings Call Transcript
Novo Nordisk A/S (NVO) Q3 2018 Earnings Conference Call November 1, 2018 8:00 AM ET Executives Lars Fruergaard Jørgensen – President and Chief Executive Officer Mads Krogsgaard Thomsen – Chief Science Officer Karsten Munk Knudsen – Chief Financial Office...
Source: SeekingAlpha
Date: November, 01 2018 16:33
Novo Nordisk A/S 2018 Q3 - Results - Earnings Call Slides
The following slide deck was published by Novo Nordisk A/S in conjunction with their 2018 Q3 earnings Read more ...
Source: SeekingAlpha
Date: November, 01 2018 11:36
Novo Nordisk Q3 revenues up 4%; shares up 3% premarket
Novo Nordisk ( NVO ) Q3 results (DKK): Revenues: 27,762M (+4.3%); R&D Expense: 23,366M (+5.2%); SG&A: 4,396M (-0.3%). More news on: Novo Nordisk A/S, Healthcare stocks news, Earnings news and commentary, Read more ...
Source: SeekingAlpha
Date: November, 01 2018 06:24
Novo Nordisk reports Q3 results
Novo Nordisk (NYSE: NVO ): Q3 GAAP EPS of DKK3.74. More news on: Novo Nordisk A/S, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 01 2018 02:40

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1448.9649.0249.1148.811,002,171
2018-01-0954.5354.8654.9654.38891,190
2018-01-0854.5654.6954.7454.3838614,045
2018-01-0554.4754.7454.7654.45645,393
2018-01-0454.6554.4954.6854.36604,232

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-123,86553,8307.1800Cover
2018-12-118,81936,73224.0090Cover
2018-12-106,87123,38029.3884Cover
2018-12-078,88016,11455.1074Short
2018-12-066,63125,32826.1805Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NVO.


About Novo-Nordisk A/S (NYSE: NVO)

Logo for Novo-Nordisk A/S (NYSE: NVO)

Novo Nordisk is the parent company of a group engaged in the development, production and marketing of pharmaceuticals, biological solutions to industrial problems vitamins, dietary supplements and digestive aids. Co. operates on a worldwide basis in two business segments: Diabetes care: discovery, development, manufacturing and marketing of products within the areas of insulin and delivery systems and oral antidiabetic products OAD . Biopharmaceuticals: discovery, development, manufacturing and marketing of products within the therapy areas haemostasis management NovoSeven R RT , growth hormone therapy, hormone replacement therapy and other products.

 

Contact Information

 

 

Current Management

  • Lars A. Sorensen / President, CEO
  • Kaare Schultz / COO
  • Jesper Brandgaard / CFO

Current Share Structure

  • Market Cap: $93,673,179,720 - 05/25/2018
  • Issue and Outstanding: 1,962,564,000 - 12/31/2017

 


Recent Filings from (NYSE: NVO)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: September, 10 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: September, 04 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: September, 04 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 28 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 20 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 20 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 20 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 14 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: August, 10 2018

 

 


Daily Technical Chart for (NYSE: NVO)

Daily Technical Chart for (NYSE: NVO)


Stay tuned for daily updates and more on (NYSE: NVO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: NVO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NVO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of NVO and does not buy, sell, or trade any shares of NVO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/